NCT05714553: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 91 | Europe | Fosifloxuridine Nafalbenamide, NUC-3373, Nucleotide analogue, Leucovorin, Folinic acid, Levo-leucovorin, Pembrolizumab, Keytruda, Docetaxel, Taxotere, Docecad, Docefrez | NuCana plc | Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer, Melanoma, Classical Hodgkin Lymphoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Subungual Squamous Cell Carcinoma, Oesophageal Carcinoma, MSI-H Colorectal Cancer, Gastric Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Pleural Mesothelioma | 08/24 | 01/25 | | |